Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.
Arsenic trioxide induces growth inhibition and apoptosis in multiple myeloma cell lines. Reducing glutathione by ascorbic acid may enhance the efficacy of arsenic trioxide. Here we report the results of an international multi-center study of arsenic trioxide in combination with ascorbic acid and dexamethasone as treatment for patients with advanced multiple myeloma.
Wu
Ka Lung
KL
Beksac
Meral
M
van Droogenbroeck
Jan
J
Amadori
Sergio
S
Zweegman
Sonja
S
Sonneveld
Pieter
P
D000328:Adult; D000368:Aged; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage*; D001205:Ascorbic Acid / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D010087:Oxides / Q000008:administration & dosage*; D012008:Recurrence
D001152:Arsenicals; D010087:Oxides; D003907:Dexamethasone; D001205:Ascorbic Acid; D000077237:Arsenic Trioxide